A simpler way to find answers

Tell us what happened. We’ll help you find the right information.

Choose a starting point or search every current campaign. You stay in control of what you share.

Instagram reel linksFind your reel →
Popular starting points

Campaigns people review often

View all campaigns

A listed review path does not mean you qualify. Read the current status and criteria before submitting.

Complete campaign directory

Every campaign, organized clearly

Search and filter campaigns

Choose a topic to see the current review status and which records may help.

How it works

A guided path, built around you

Read about your situation, see which records may help, and choose whether to request a review.

  1. 1
    Choose what happenedStart with a category or search.
  2. 2
    Read the campaign informationCheck status, criteria, and sources.
  3. 3
    Answer relevant questionsThe intake adapts to your answers.
  4. 4
    Receive the next stepA review does not guarantee acceptance.
Understand the complete process

Find topics that match your situation

Clear by design

Navigate with confidence

01

Current status and review dates

See when each campaign was checked and whether a private review is available.

02

Official source links

Open the court or agency source behind each published update.

03

Evidence checklists

Understand which records and dates may help before starting a form.

04

Clear privacy choices

Review consent language before sharing your information.

05

Accessible everywhere

Use the same guided path on phone, tablet, or desktop.

Verified updates

Mass tort developments from the courts and agencies tracking them.

Latest source review
Latest update
U.S. District Court for the Eastern District of North Carolina, Mousser v. United States, No. 7:23-cv-00667, ECF 130

Camp Lejeune plaintiff submits proposed findings after kidney cancer trial

After an October bench trial, Frank Mousser asked the judge to find that exposure to contaminated water at Camp Lejeune caused his cancer. His November 15 filing proposes judgment in his favor and sets out the damages and deductions he seeks. The proposed order leaves the judge’s signature and date blank. The court will decide what findings to adopt.

View official source Verified
More on this case

More recent updates

U.S. Food and Drug Administration

FDA requires GLP-1 labels to address a possible risk of optic nerve injury

Summary and source

The FDA directed manufacturers to update the warnings for GLP-1 medicines after reviewing evidence about NAION, a rare optic nerve condition that can cause permanent vision loss. The agency described a potential increase in risk. Its review included clinical trials and observational studies.

View official source Verified
More on this case
Start with information

Find the campaign that fits what happened.

Read the current status, review the source information, and continue only when you are comfortable.

Browse all campaigns